Top

Published in:

01-12-2010 | Day-to-Day Practice

Use of rituximab in three children with relapsed/refractory Burkitt lymphoma

Authors: Sinan Akbayram, Murat Doğan, Cihangir Akgün, Fatih Erbey, Hüseyin Çaksen, Ahmet Faik Öner

Published in: Targeted Oncology | Issue 4/2010

Abstract

Monoclonal antibodies have provided new promise for patients with B-cell malignancies. Rituximab is a monoclonal antibody against B-lymphocytes that express CD20; it is used for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Very few data are available regarding the treatment of children with non-Hodgkin lymphoma with rituximab. In this article, we reported three children with primary refractory/relapsed B-cell-non-Hodgkin lymphoma, who were successfully treated with a combination of intensive chemotherapy protocol plus rituximab. In all three of our cases, the patients are still in complete remission. Our aim is to emphasize the importance of use of rituximab in the treatment of childhood B-cell non-Hodgkin lymphoma.

Dormann S, Duffner U, Martini C et al (2002) Brief report: chronic myelopathy after combined chemo-radiotherapy in a patient with relapsed mediastinal B-cell lymphoma. Med Pediatr Oncol 38:442–444CrossRefPubMed

Sandlund JT, Downing JR, Crist WM (1996) Non-Hodgkin’s lymphoma in childhood. N Engl J Med 334:1238–1248CrossRefPubMed

Griffin TC, Weitzman S, Weinstein H (2009) A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer 52:177–181CrossRefPubMed

Attias D, Weitzman S (2008) The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr 20:17–22CrossRefPubMed

Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456–473CrossRefPubMed

Shabbat S, Aharoni J, Sarid L et al (2009) Rituximab as monotherapy and in addition to reduced CHOP in children with primary immunodeficiency and non-Hodgkin lymphoma. Pediatr Blood Cancer 52:664–666CrossRefPubMed

Manolopoulos L, Gomatos IP, Leandros E et al (2009) Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin’s lymphoma of the head and neck. In Vivo 23:475–478PubMed

Bay A, Dogan M, Acikgoz M et al (2007) Rituximab in a child with relapsed Burkitt lymphoma. Pediatr Blood Cancer 49:218CrossRefPubMed

Corbacioglu S, Eber S, Gungor T et al (2003) Induction of long-term remission of a relapsed childhood B-ALL with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. J Pediatr Hematol/Oncol 25:327–329CrossRef

10.

Vries MJ, Veerman AJ, Zwaan C (2004) Rituximab in three children with relapsed/refractory B-cell ALL/Burkitt NHL. Br J Haematol 125:405–417CrossRef

11.

Culic S, Culic V, Armanda V et al (2003) Anti-CD20 monoclonal antibody (rituximab) for therapy of mediastinal CD20 positive large B-cell NHL with a local tumor extension into lung of a 10-year-old girl. Pediatr Hematol Oncol 20:339–344PubMed

12.

Ozsahin H, Fluss J, McLin V et al (2002) Rituximab with IL-2 after autologous bone marrow transplantation for ALL in second remission. Med Pediatr Oncol 38:300–301CrossRefPubMed

13.

Heath JA, Broxson EH, Dole MG et al (2002) EBV associated lymphoma in a child undergoing an autologous stem cell rescue. J Pediatr Hematol/Oncol 24:160–163CrossRef

14.

Meinhardt A, Burkhardt B, Zimmermann M et al (2010) Berlin-Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol 28:3115–3121CrossRefPubMed

15.

Coiffier B, Haioun C, Ketterer N et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927–1932PubMed

16.

Leget GA, Czuczman MS (1998) Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 10:548–551CrossRefPubMed

17.

Song KW, Mollee P, Patterson B et al (2002) Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 119:125–127CrossRefPubMed

18.

Quartier P, Brethon B, Philippet P et al (2001) Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511–1513CrossRefPubMed

19.

Zecca M, Nobili B, Ramenghi U et al (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–3861CrossRefPubMed

20.

Scheinberg M, Hamerschlak N, Kutner JM et al (2006) Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002–2004). Clin Exp Rheumatol 24:65–69PubMed

21.

Giulino LB, Bussel JB, Neufeld EJ, Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network (2007) Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr 150:338–344CrossRefPubMed

22.

Vose JM, Link BK, Grossbard ML et al (2001) Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 19:389–397PubMed

23.

Wilson WH, Gutierrez M, O’Connor P et al (2002) The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of doseadjusted EPOCH-R. Semin Oncol 29:41–47CrossRefPubMed

24.

Winkler U, Schulz HR, Klein TO (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217–2224PubMed

25.

Stel AJ, ten Cate B, Jacobs S et al (2007) Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis. J Immunol 178:2287–2295PubMed

Title: Use of rituximab in three children with relapsed/refractory Burkitt lymphoma
Authors: Sinan Akbayram
Murat Doğan
Cihangir Akgün
Fatih Erbey
Hüseyin Çaksen
Ahmet Faik Öner
Publication date: 01-12-2010
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 4/2010
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-010-0161-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Targeting mTOR in cancer: renal cell is just a beginning

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality

Tufted hair folliculitis in a woman treated with trastuzumab

Examining the safety profile of angiogenesis inhibitors: implications for clinical practice

Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer